Pfizer Inc. (NYSE: PFE) reported third quarter 2023 earnings results today. Revenues declined 42% year-over-year to $13.2 billion. The company reported a
PFE Earnings: Key quarterly highlights from Pfizer’s Q3 2023 financial results
Categories
Health Care
BMY Earnings: Highlights of Bristol-Myers Squibb’s Q3 2023 results
Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported mixed results for the third quarter of 2023. The company also provided guidance
Merck (MRK) Earnings: 3Q23 Key Numbers
Merck (NYSE: MRK) reported sales of $16 billion for the third quarter of 2023, up 7% from the same period a year
ABBV Earnings: A snapshot of AbbVie’s Q3 2023 report
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced third-quarter 2023 financial results, reporting lower revenues and net income. The company reported
Key highlights from Thermo Fisher’s (TMO) Q3 2023 earnings results
Thermo Fisher Scientific Inc. (NYSE: TMO) reported third quarter 2023 earnings results today. Revenue dropped 1% year-over-year to $10.57 billion. Organic revenues
Earnings Summary: Highlights of Centene Corp’s Q3 2023 earnings report
Healthcare service provider Centene Corporation (NYSE: CNC) on Tuesday announced third-quarter 2023 earnings results, reporting a sharp increase in revenues and adjusted
Ocean Biomedical’s chief scientist Dr. Jonathan Kurtis receives Falk Award for malaria drug candidate
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said its chief scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk
Intuitive Surgical stock dips after mixed Q3 earnings. What’s in store?
Intuitive Surgical, Inc. (NASDAQ: ISRG) produces and sells some of the most advanced robotic surgical systems that make medical procedures simpler and
ISRG Earnings: Intuitive Surgical Q3 2023 revenues and earnings increase
Medical device company Intuitive Surgical, Inc. (NASDAQ: ISRG) announced operating results for the third quarter of 2023, reporting higher revenues and adjusted
Infographic: Key highlights from Abbott Laboratories’ (ABT) Q3 2023 earnings results
Abbott Laboratories (NYSE: ABT) reported third quarter 2023 earnings results today. Net sales decreased 2.6% year-over-year to $10.1 billion. On an organic basis,
JNJ Earnings: All you need to know about Johnson & Johnson’s Q3 2023 earnings results
Johnson & Johnson (NYSE: JNJ) reported third quarter 2023 earnings results today. Reported sales increased 6.8% year-over-year to $21.3 billion. Operational sales
Infographic: How UnitedHealth Group (UNH) performed in Q3 2023
UnitedHealth Group (NYSE: UNH) reported third quarter 2023 earnings results today. Revenues grew 14% year-over-year to $92.4 billion. Net earnings attributable to
Ocean Biomedical forms JV with Virion Therapeutics to find treatments for cancer and chronic infectious diseases
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) entered into a joint venture with Virion Therapeutics, LLC, to expedite and expand the latter’s
Walgreens Boots Alliance (WBA) Q4 2023 Earnings: Key financials and quarterly highlights
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) reported fourth quarter 2023 earnings results today. Sales increased 9.2% year-over-year to $35.4 billion. Sales growth
Johnson & Johnson to report earnings on Oct 17. Here’s what to look for
After reporting better-than-expected quarterly earnings consistently for over a decade, healthcare behemoth Johnson & Johnson (NYSE: JNJ) is preparing to release its
UnitedHealth earnings preview: Another beat in cards despite cost concerns
Over the years, UnitedHealth Group Incorporated (NYSE: UNH) has expanded steadily through diversification and acquisitions, all along creating value for shareholders. The
What to look for when Walgreens Boots Alliance reports earnings on Oct. 12
Retail pharmacy chain Walgreens Boots Alliance, Inc. (NASDAQ: WBA) is on the path to a transformation as it looks to align the
Infographic: AngioDynamics reports adjusted loss for Q1 2024; sales down 4%
AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a net loss, on an adjusted basis, for the first quarter of 2024 when its
Ocean Biomedical announces loan commitment of up to $10 million from largest stockholder
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers to develop and commercialize their discoveries,
Ocean Biomedical’s cancer-targeting antibody candidate shows effective tumor reduction against a subset of NSCLC with EGFR mutations
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biotechnology company that operates by partnering with leading researchers to accelerate new discoveries in the healthcare
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates